Drug development ... from genomics-based precision medicines, so there is still an unmet need for biomarkers. The Xerna TME panel looks at the biologies of the tumor microenvironment that are ...

Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the efficacy ...

An immuno-oncology targeting panel accurately characterized tumor-resident immune cells and located pathologically and clinically relevant tumor microenvironment features ... for neurological research ...

With a global footprint across three continents, Cancer Genetics, Inc. (CGIX) has been supporting innovative drug discovery and biomarker development programs in oncology and immuno-oncology at ...

Potential in drug discovery Owkin’s tools and business extend beyond being able to provide insights for the future treatment of kidney cancer ... be taken and a precision medicine could be ...

Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations.

He will also showcase its performance through benchmarking studies, applications in ovarian cancer cell lines and its capability ... supporting preclinical and clinical workflows in drug discovery.

The Translational Cancer Medicine Program ... This enables the discovery and validation of the biomarker signatures that associate with the drug efficacy profiles of individual patients, paving the ...

--(BUSINESS WIRE)--Scipher Medicine, a leader in precision medicine for autoimmune ... a strategic partnership to advance rheumatology drug discovery and development by integrating Scipher ...

allowing for advanced studies of the tumor microenvironment (TME) and serving as preclinical models for gene editing, molecular profiling, drug testing, and biomarker discovery—crucial for ...